Search Results - "Melear, J."

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

Authors: Coombes RC Howell S Lord SR et al.

Source: Nature communications [Nat Commun] 2023 Aug 07; Vol. 14 (1), pp. 4741. Date of Electronic Publication: 2023 Aug 07.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; PubMed not MEDLINE

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

Authors: Coombes RC Howell S Lord SR et al.

Source: Nature communications [Nat Commun] 2025 Mar 06; Vol. 16 (1), pp. 2242. Date of Electronic Publication: 2025 Mar 06.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; PubMed not MEDLINE

Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)—a trial by Asian Myeloma Network (NCT03695744).

Authors: Tan, Melinda S. Y. Nagarajan, Chandramouli Ooi, Melissa et al.

Source: Leukemia & Lymphoma. Feb2026, Vol. 67 Issue 3, p600-607. 8p.

Complex Chromothripsis-like Features in Plasma Cell Myeloma: A Case Report and Review of the Literature.

Authors: Oentoro, Jaymie Yu, Sonia Murgas, Kevin A. et al.

Source: Diagnostics (2075-4418). May2026, Vol. 16 Issue 9, p1280. 10p.

Advances in First-Line Treatment of Classical Hodgkin Lymphoma in the Era of Novel Agents.

Authors: Barefah, Ahmed Salleh^1,2 (AUTHOR)

Source: Journal of Clinical Medicine. Jul2026, Vol. 15 Issue 13, p5075. 18p.

Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism.

Authors: Yang, Yilan Liao, Jiatao Pan, Zhe et al.

Source: Advanced Science. 2/3/2025, Vol. 12 Issue 5, p1-15. 15p.

Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium.

Authors: Fahey, Catherine C. Clark-Garvey, Sean Porten, Sima et al.

Source: Current Oncology. May2025, Vol. 32 Issue 5, p278. 11p.

The Evolving Landscape of Anti-Clonal Therapy in Newly Diagnosed Systemic Light-Chain (AL) Amyloidosis: Evidence- and Time-Based Comparison with Multiple Myeloma.

Authors: Ríos-Tamayo, Rafael^1,2,3 (AUTHOR)

Source: Life (2075-1729). Feb2026, Vol. 16 Issue 2, p363. 18p.

AXL Inhibitors in Oncology Clinical Trials: A Review.

Authors: Quach, Ethan Sanginova, Farahnoz Cheruku, Anish et al.

Source: Journal of Immunotherapy & Precision Oncology. 2026, Vol. 9 Issue 1, p1-16. 16p.

Advances in Targeting Growth Factor Signalling in Neuroblastoma and Overcoming Drug Resistance.

Authors: Ivanenko, Karina Shaymardanov, Ruslan Prassolov, Vladimir et al.

Source: Cells (2073-4409). Jan2026, Vol. 15 Issue 1, p4. 43p.

Strategic Combinations of Antibody–Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens.

Authors: Jang, Heewon Chang, Ji-Eun

Source: Pharmaceutics. Dec2025, Vol. 17 Issue 12, p1581. 53p.

Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.

Authors: Eleutherakis Papaiakovou, Evangelos Terpos, Evangelos Kanellias, Nikolaos et al.

Source: Leukemia & Lymphoma. Dec2023, Vol. 64 Issue 13, p2140-2147. 8p.

The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of Treatment.

Authors: Amsterdam, Dana Grossberger, Ori Melamed, Natan et al.

Source: Cancers. Oct2024, Vol. 16 Issue 19, p3329. 10p.

Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma.

Authors: Paul, Barry Anwer, Faiz Raza, Shahzad et al.

Source: Cancers. Sep2024, Vol. 16 Issue 17, p2938. 13p.

Molecular Insights and Therapeutic Advances in Low-Risk Myelodysplastic Neoplasms: A Clinical Review.

Authors: Dhillon, Vikram Maciejewski, Jaroslaw Balasubramanian, Suresh Kumar

Source: Cancers. Nov2025, Vol. 17 Issue 22, p3610. 23p.

Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies.

Authors: Zhou, Kexun Liu, Xinrui Zhu, Hong

Source: Journal of Hematology & Oncology. 11/3/2025, Vol. 18 Issue 1, p1-43. 43p.

Non-producer multiple myeloma presenting with acute hyperammonemic encephalopathy: case report.

Authors: Verma, Karina Zhang, Tina Mueller, David et al.

Source: Diagnostic Pathology. 1/4/2023, Vol. 18 Issue 1, p1-5. 5p.

Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China.

Authors: Han, Xiaoyan Jiang, Xincheng He, Jingsong et al.

Source: Cancer Medicine. May2024, Vol. 13 Issue 9, p1-15. 15p.

Prospects and Challenges of Different Delivery Systems in Breast Tumors Therapy.

Authors: Mai, Cunjun Tang, Huiyang Lai, Guie et al.

Source: Breast Cancer: Basic & Clinical Research. 8/15/2025, p1-19. 19p.

Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy.

Authors: Atrash, Shebli Mammadzadeh, Aytaj Peng, Fulei et al.

Source: Cancers. Jun2023, Vol. 15 Issue 11, p2891. 13p.